Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Payables (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Payables for 15 consecutive years, with $13.7 million as the latest value for Q1 2026.

  • For Q1 2026, Payables changed 0.15% year-over-year to $13.7 million; the TTM value through Mar 2026 reached $13.7 million, changed 0.15%, while the annual FY2025 figure was $18.4 million, 10.29% up from the prior year.
  • Payables hit $13.7 million in Q1 2026 for Agios Pharmaceuticals, down from $18.4 million in the prior quarter.
  • Across five years, Payables topped out at $19.6 million in Q3 2025 and bottomed at $7.8 million in Q2 2022.
  • Average Payables over 5 years is $13.5 million, with a median of $13.3 million recorded in 2023.
  • Year-over-year, Payables plummeted 77.45% in 2022 and then surged 74.71% in 2025.
  • Agios Pharmaceuticals' Payables stood at $18.6 million in 2022, then crashed by 47.46% to $9.8 million in 2023, then skyrocketed by 70.17% to $16.6 million in 2024, then grew by 10.29% to $18.4 million in 2025, then decreased by 25.1% to $13.7 million in 2026.
  • According to Business Quant data, Payables over the past three periods came in at $13.7 million, $18.4 million, and $19.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.